DSM Anti-Infectives News

DSM Anti-Infectives, a business group of Royal DSM N.V., the global life sciences and materials sciences company headquartered in the Netherlands, and Mumbai (IN) based Arch Pharmalabs Ltd., a pharmaceutical company manufacturing active pharmaceutical ingredients (APIs), have signed a partnership agreement.

All REACH-related actions within DSM are guided by a Steering Group of business group managers and senior executives, supported by an Expert Team and a dedicated Sourcing Team. In addition to this every business group has its own REACH Taskforce.

Within this framework DSM Anti-Infectives is preparing for the pre-registration of all substances that it produces or imports.

Carve-out of business group. Impairment of some EUR 110 million net in Q2 2007.

Global leader DSM Anti-Infectives today announced the launch of its breakthrough technology in India, in succession to its first production facility in Spain with the introduction of Purimox® an antibiotic with highest purity.

DSM will invest in the expansion of DSM Anti-Infectives’ production facilities at Toansa (India). The investment will increase production of the penicillin-related intermediate 6-APA and of active pharmaceutical ingredients (APIs).

Today, DSM Deretil, global leader in the field of development, production and sales of side chains for betalactamic antibiotics and the Chinese company Shangyu Yuntao Chemicals, announced that they have formed a Joint Venture for the production of DL Phenyl Glycine and D(-) Phenyl Glycine. DSM Deretil acquired 51% of the shares and obtained an option to acquire the remaining 49% to gain full ownership of the company within the next three years.